Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

4th RNA-Seq San Francisco April 26-28 Event Guide

4th RNA-Seq moved to San Francisco in 2016 and is dedicated to Single-Cell RNA-Seq as well as Analyzing the Clinical Applications of RNA-Seq

  • Login to see the comments

  • Be the first to like this

4th RNA-Seq San Francisco April 26-28 Event Guide

  1. 1. April 26 - 28, 2016 San Francisco, CA 24 Expert Speakers Including: Lead Partner: Additional Partners: www.rna-seqsummit.com Researched & Developed By: Tel: +1 212 537 5898 | Email: info@hansonwade.com RNA-Seq Forum • Harnessing the Full Potential of Single-Cell RNA-Seq • Reinventing Analytical Strategies to Deal with the Vast Complexity of the Transcriptome • Advancing the Clinical Applications of RNA-Seq Technology 2016 RNA-Seq 2016 San Francisco | April 26-28, 2016 Paul Rejto Head of Precision Medicine, Oncology Research Unit Pfizer Yasuhiro Funahashi Senior Director, Biomarkers and Personalized Medicine Core Function Unit Eisai ® Chris Mason Principal Investigator and Associate Professor Weill Cornell Medical College Ganesh Sathe Head of DNA Sequencing GSK Dongliang Ge Director, Computational Biology Gilead Sciences Garry Nolan Professor, Microbiology & Immunology Stanford University @RNASeq_Summit
  2. 2. RNA-Seq Forum 1 6 3 8 2 7 4 9 5 10 Welcome to RNA-Seq 2016 Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit Realize the Practical Applications of RNA-Seq In an industry that is constantly evolving, the integration and application of RNA-Seq technologies to improve drug discovery and development is gaining significant momentum. RNA-Seq 2016 will help expert scientists, bioinformaticians and business leaders devise collaborative solutions to streamline technology and maximize the practical applications of RNA-Seq. Critically, this year’s agenda has been designed specifically for the RNA-Seq community by fore-thinkers in the industry with a greater focus on single-cell RNA-Seq, bioinformatics approaches and the clinical applications of RNA-Seq. By engaging with our expert speaker line-up, you will get the chance to hear the most up to date case studies, intellectual insight and be part of this thought provoking discussion. Join the 4th annual RNA-Seq meeting to evaluate the latest advances in RNA-Seq, and discover how to fully utilize this technology to advance disease understanding and therapeutic intervention. Harness the full potential of single-cell RNA-Seq to revolutionize the way we approach disease research Implement specific bioinformatic systems for accurate analysis of clinical genomic studies Top 10 Reasons to Attend RNA-Seq 2016 Develop analytical strategies to accurately interpret the vast complexity of the transcriptome and efficiently source the most valuable information Successfully utilize metatranscriptomics to advance progression in microbiome disease research Identify innovative, cutting edge methodologies to improve single-cell sequencing throughput and efficiency Engage in debate with bioinformaticians and biologists to streamline the RNA-Seq process from the bench to the computer Understand how to effectively develop RNA-Seq technologies into clinically applicable tools Identify methods of commercializing RNA-Seq for biomarker detection and as a clinical diagnostic tool Successfully integrate RNA-Seq with the other omic studies to generate combinatorial strategies for furthering disease understanding Overcome the shortfalls in current RNA-Seq technologies to drive the evolution of cheaper and more efficient systems Some of the brightest minds and industry leaders in genomics for a series of illuminating seminars and beneficial meetings. Bina Technologies RNA-Seq Attendee
  3. 3. RNA-Seq Forum Speakers Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com @RNASeq_Summit RNA-Seq 2016 San Francisco | April 26-28, 2016 Yasuhiro Funahashi Senior Director, Biomarkers & Personalized Medicine Core Function Unit Eisai Jeff Brockman Principal Scientist Hill’s Pet Nutrition Tim Mercer Lab Head, Transcriptomic Research Garvan Institute of Medical Research Alex Shalek, Assistant Professor of Health Sciences & Technology MIT Alex Mackenzie Principal Investigator, Apoptosis Research Centre CHEO Research Institute Zoltan Dezso Principal Scientist, Human Biology & Data Sciences Engine Eisai Magnolia Bostick Scientist III Takara Clontech Jamie Hill Senior Bioinformatics Scientist QIAGEN Saumya Pant Head of Sequencing Technologies Bristol-Myers Squibb Xiang (Sean) Yao Principal Scientist CS - Computational & System Biology Janssen Alex Pollen Damon Runyon Postdoctoral Fellow UCSF Karsten Zengler Associate Professor, Division of Host-Microbe Systems & Therapeutics University of California, San Diego Kejie Li Computational Biologist Biogen Idec Jadwiga Bienkowska Director, Computational Biology Pfizer Josh Kaminker Senior Scientist, Bioinformatics & Computational Biology Genentech Garry Nolan Professor, Microbiology & Immunology Stanford University Jin Jen Co-Director, Genome Analysis Core, Medical Genome Facility Mayo Clinic Dongliang Ge Director, Computational Biology Gilead Sciences Kelli Bramlett Leader RNA Sequencing Applications Team, Life Sciences Solutions Thermo Fisher Scientific Stefan McDonough Senior Director & Head of Neurogenetics Pfizer Paul Rejto Head of Precision Medicine, Oncology Research Unit Pfizer Ganesh Sathe Head of DNA Sequencing GSK Jean-Noel Billaud Principal Scientist QIAGEN Chris Mason Principal Investigator & Assistant Professor Weill Cornell Medical College
  4. 4. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit 8.20 Chair’s Opening Remarks 8.30 Keynote Presentation: Towards a Cellular & Molecular Resolution Map of Cerebral Cortex Development • Creating a cellular resolution map of gene expression in the developing human neocortex to unravel the diversity of neuronal lineages and to support strategies for targeting and replacing specific cell types in the brain • Analyzing gene expression across single cells to identify the outer subventricular zone radial glia preferentially express genes that may help to establish a self- sustaining proliferative stem cell niche • Developing strategies to integrate data from single cell genomics with studies of morphology, position, cell behavior, developmental fate potential, and physiology Alex Pollen, Damon Runyon Postdoctoral Fellow, UCSF The Single-Cell RNA-Sequencing Revolution 9.00 Addressing Cancer Heterogeneity at the Single-Cell Level • Effectively utilizing single-cell RNA-Seq to elucidate tumor heterogeneity • Identifying epigenetic drivers of gene expression heterogeneity in cancer using single- cell RNA-Seq • Efficiently analyzing and integrating transcriptional and epigenetic data in cancer genomics research Chris Mason, Principal Investigator and Associate Professor, Weill Cornell Medical College 9.30 Successfully Deconvolving Heterogeneous Systems Using Single-Cell RNA-Seq to Increase Disease Understanding • Improving understanding of cellular heterogeneity in the context of disease progression • Identification of cell differentiation with relevance to homeostasis and disease pathogenesis • Analyzing the discovery of detailed cellular phenotypes to drive target identification and therapeutic discovery Alex Shalek, Assistant Professor of Health Sciences & Technology, MIT 10.00 Morning Refreshments & Speed Networking 11.00 Utilizing Single-Cell RNA-Seq For Fluid Biopsies Analysis • Deploying single-cell RNA-Seq for clinically accurate analysis of disease biopsies • Overcoming the hurdles of analyzing biofluid RNA samples with single-cell sequencing • Adapting experimental design and analytical methods to accommodate for biofluid RNA sample input • Identification of current obstacles to single-cell RNA-Seq to streamline single-cell RNA-Seq pipelines Saumya Pant, Head of Sequencing Technology, Bristol-Myers Squibb 11.30 The Billion Cell Barcode Revolution • Harnessing split pool synthesis combinatorial chemistry as an alternative approach in single-cell sequencing to barcode billions of cells without cellular isolation • Understanding how to successfully integrate split pool synthesis into an single-cell RNA-Seq pipeline • Applying this revolutionary protocol in a disease specific context Garry Nolan, Professor, Microbiology & Immunology, Stanford 12.00 Networking Lunch Tackling Functional Transcriptome Complexity 1.00 Systematic Integration of RNA-Seq Data & Application to Drug Discovery Research • Integration internal and external RNA-Seq data, such as GTEx and ENCODE, through consistent data processing and cross-linking • Multi-tier management of different RNA-Seq data types and access levels • Application of integrative RNA-Seq analysis to drug discovery, especially in various aspects of target identification and validation Xiang (Sean) Yao, Principal Scientist,  CS - Computational and System Biology, Janssen 1.30 Overview of RNA-Seq Applications in Cancer Drug Discovery • Utilizing RNA-Seq in cancer drug discovery will be reviewed with applications to target discovery, undercovering mechanisms of resistance, and providing insight into predictive markers for response to therapy • Analyzing future directions and new applications including liquid biopsies, rare cell populations and poor quality tissue Paul Rejto, Head of Precision Medicine, Oncology Research Unit, Pfizer Conference Day One, April 27, 2016
  5. 5. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit 2.00 Defining RNA Quality Control Metrics to Improve the Study of Full Transcriptional Complexity • The design, manufacture and validation of synthetic genes for bioinformatics analysis of gene expression, transcript assembly and fusion gene diagnostics • Comprehensive analysis of human chromosome 21: detailing the full extent of transcriptome size and complexity • Identification of fundamental distinctions between coding and non-coding gene organisation, splicing and evolution Tim Mercer, Lab Head, Transcriptomic Research, Garvan Institute of Medical Research 2.30 RNA-Seq Simplified! Targeted NGS Approaches to RNA Analysis • Discussing the use of Ion AmpliSeq™ technology for targeted RNA analysis • Analysis of data confirming high sensitivity, broad dynamic range and assay robustness • Utilizing this approach for gene pathway analysis, gene fusion detection, and transcriptome analysis Kelli Bramlett, Leader, RNA Sequencing Applications Team, Life Sciences Solutions, Thermo Fisher Scientific 2.40 Using RNA-Seq to Study the Gastrointestinal Tract of the Dog • Addressing RNA integrity and endogenous RNAse expression in the upper sections of the GI tract • Defining functional compartments of the GI tract through utilization of gene expression patterns • Studying the correlation between specific mRNA expression levels and attachment of gut microflora Jeff Brockman, Principal Scientist, Hill’s Pet Nutrition 3.10 Afternoon Refreshments & Networking 3.40 NGS & RNA-Seq in  Cancer Immune Therapy • Utilizing RNA-Seq to Study Protein-RNA interactions • Understanding how RNA-Seq can be used to study the impact of differential exon expression on protein function • Employing RNA-Seq in conjunction with other sequencing methods for the identification and observation of protein-RNA interactions in subcellular detail Jadwiga Bienkowska, Director, Computational Biology, Pfizer 4.10 Deciphering the Cellular Complexities of Neurodegenerative Disease using RNA-Seq • Developing novel methods to purify specific populations of cells from whole brain • Performing RNA-Seq analysis using low quantity and low quality RNA • Transcriptomic analysis identifies cell specific expression and splicing changes in neurodegenerative disease Josh Kaminker, Senior Scientist, Bioinformatics & Computational Biology, Genentech 4.40 Panel Discussion: The Significance of Transcriptome Complexity • Evaluating RNA sequencing technologies and bioinformatic tools that resolve transcriptome complexity. • Debating the functional importance of pervasive transcription, long noncoding RNAs, and isoform diversity generated by extensive alternative splicing. • Discussing the role of transcriptome complexity in evolution, development and disease Tim Mercer, Lab Head, Transcriptomic Research, Garvan Institute of Medical Research Alex Shalek, Assistant Professor of Health Sciences and Technology, MIT Jeff Brockman, Principal Scientist, Hill’s Pet Nutrition Josh Kaminker, Senior Scientist, Bioinformatics & Computational Biology, Genentech Alex Pollen, Damon Runyon Postdoctoral Fellow, UCSF 5.20 Round Table Session This session will focus on devising solutions that cannot be obtained in presentation format, and will give you actionable takeaways to build a more holistic understanding of the field. Access the critical information that is only obtainable through frank and open discussion around crucial topics in the field. Shape the debate around the following topics: • How many cells do you need? – e.g.  What are the drivers of the quantity of single cells you need to look at for your experiment • Single Cell RNA Seq Bioinformatics • The power of full length transcript RNAseq – e.g. when to run full length transcript vs 3’ end counting to answer you biological question 6.20 Chair’s Closing Remarks 6.30 Networking Drinks Reception hosted by Fluidigm ® ®
  6. 6. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit 8.50 Chair’s Opening Remarks Analyzing the Clinical Applications of RNA Sequencing 9.00 Panel Discussion: Debating the Clinical Applications of RNA-Seq • Understanding the approval standards for clinical applications of RNA-Seq • Revamping the regulatory system to support the innovation and application of RNA- Seq in the clinic • Defining the regulatory framework to identify the procedures for delivering clinically useful RNA-Seq products • How to best analyze, interpret and present RNA-Seq data to maximize a clinically relevant output • Incorporating RNA-Seq into clinical management and practices: identifying how to best utilize RNA-Seq in the clinic Ganesh Sathe, Head DNA Sequencing, GSK Stefan McDonough, Executive Director, Research, Amgen 9.45 Utilizing RNA-Seq for Translational Research to identify Biomarker for Anticancer Agents Targeting Tumor Microenvironment • Employing RNA-Seq for cancer biomarker research to target tumor microenvironment • Issues of RNA-Seq analysis and targeting approach with other methods to promote translation science in clinical biomarker • Discussing the utility of RNA-Seq analysis based on examples of the translational research for our anticancer drugs Yasuhiro Funahashi, Senior Director, Biomarkers and Personalized Medicine Core Function Unit, Eisai 10.15 Harnessing the Potential of RNA-Seq as a Clinical Diagnostic Tool • Employing transcriptome profiling for disease analysis and compound verification • How to best use differential gene expression signatures to identify small molecules for compound screening • Utilizing RNA-Seq technology for accurate profiling and analysis of ALS neurodegenerative disease Ganesh Sathe, Head DNA Sequencing, GSK 10.45 New Applications Leveraging RNA Sequencing using SMART Technology • Three new applications for low input RNA analysis • Using SMART technology to generate libraries for RNA profiling for: • Small RNAs • TCR (T cell receptor) • Single cells using the Fluidigm C1 Magnolia Bostick, Scientist III, Takara Clontech 10.55 Morning Refreshments & Networking 11.30 Overcoming RNA Quality Issues to Enable High Quality Whole Transcriptome Sequencing • Critical factors affecting the quality of RNA in clinical and research settings • Optimized protocols for RNA-Seq using challenging and partially degraded samples • Clinical applications of RNA-Seq to enhance cancer diagnosis and treatment stratification Jin Jen, Co-Director, Genome Analysis Core, Mayo Clinic 12.00 Harnessing RNA-Seq in Drug Repurposing for Rare Genetic Disorders • Utilizing RNA-Seq to validate specific rare diseases as potential candidates for drug repurposing programs • Devising analytical strategies to identify potential drugs that transcriptionally modulate specific disease genes • Proving efficacy of potentially repurposable drugs and the restoration of normal genetic function using RNA-Seq Alex Mackenzie, Principal Investigator, CHEO Research Institute Conference Day Two, April 28, 2016
  7. 7. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit 12.30 Networking Lunch 1.30 Overcoming Bioinformatic Challenges in Clinical Genomics • Identifying the key big data issues in drug discovery and development • Choosing a big data strategy for biomarker development • Discussing common pitfalls when planning an NGS led study • Best practices in the evaluation of the quality of NGS data Dongliang Ge, Director Computational Biology, Gilead Sciences 2.00 Application of Single Cell RNA-Seq on Clinical Biopsy Material at Biogen • Benchmarking study of the comparison of RNA-Seq to other profiling platforms • Findings of single cell RNA-Seq analysis of clinical biopsy sample • For extreme low amount of biopsy sample, reconstituting single cell RNA-Seq profiles to bulk sample like profile as an alternative Kejie Li, Computational Biologist, Biogen Idec 2.30 Afternoon Refreshments & Networking 3.00 Utilizing RNA-Seq Data for Biomarker Research in Cancer Immunotherapy • Identifying the immunophenotypes of different types of cancer by applying computational methods on large scale RNA-Seq data • Exploring how cancer immunophenotyping supports patient stratification and biomarker research in cancer immunotherapy • Understanding the relationship between cancer immunophenotypes with immune genes and signaling pathways based on RNA-Seq expression profiling Zoltan Dezso, Principal Scientist, Human Biology & Data Sciences Engine, Eisai 3.30 Panel Discussion: Creating Efficient Collaborations Between Bioinformaticians & Biologists to Harmonize RNA-Seq Procedures • Streamlining the RNA-Seq process between the bench and computer • Matching experimental design and analytical strategies to accurately and efficiently interpret RNA-Seq data • How to fully utilize sequencing and analysis of the transcriptome to inform disease understanding and drug discovery and development • Improving our understanding of the transcriptome and developing better analysis strategies to deal with the sheer amount of transcriptional complexity • Debating methods to make sequencing data analysis simpler, faster and cheaper • Shifting towards a more targeted analytical approach defined by disease context and specific sequencing application Paul Rejto, Head of Precision Medicine, Oncology Research Unit, Pfizer Dongliang Ge, Director, Computational Biology, Gilead Sciences Zoltan Dezso, Principal Scientist, Human Biology & Data Sciences Engine, Eisai 4.15 Chair’s Closing Remarks 4.20 End Day Two & Close of Conference Excellent panel of speakers providing a comprehensive overview of the field Vertex Pharmaceuticals RNA-Seq Attendee
  8. 8. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit Pre- Conference Workshop - A The concept of a liquid biopsy has been around for some time, but is now fast becoming the leading technology for new diagnostics to detect early stage cancer resulting in more successful treatment, and to monitor cancer progression after treatment. While much of the focus in liquid biopsy has been on sequencing the DNA circulating in the patient’s blood, a recent paper in Nature Cell Biology entitled “Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver” researchers are focusing on exosomes circulating in the bloodstream; specifically the RNA contained within these exosomes. Pancreatic cancer is one of the most lethal cancers due in part to the difficulty in early diagnosis and treatment. Researchers believe sequencing RNA from tumor derived exosomes circulating in the patient’s blood could lead to early diagnosis and treatment. This workshop will include in-depth coverage of the bioinformatics solutions used to analyze and interpret RNA-sequencing results from these exosome experiments providing additional hypothesis on regulatory networks and potential isoforms of biological significance. By attending this workshop you learn about and discuss the following: • Take a deep dive and understand how to optimize the analysis of RNA-sequencing results to get the most out of each RNA-seq experiment • Standardize RNA-sequencing data analysis using industry leading algorithms and statistical testing • Understand scalable approaches to sequencing data analysis and optimize the ROI across the organization for sequencing experiments • Evaluate a biologist approach to streamlining R NA-sequencing alignment and analysis using configured workflows for the fast track to biological interpretation • Analyze exosome gene expression signatures to pinpoint significant genes associated with early detection of pancreatic cancer • Identify significantly differentially expressed isoforms and their association to pancreatic cancer • Generate novel regulatory networks as hypotheses suggesting drivers of the expression changes observed in these tumor producing exosomes to better understand pancreatic cancer drivers. Transcriptome Analysis of Pancreatic Cancer Exosomes Reveal Pathways & Biological Processes Involved in Metastatic Progression Date: April 26, 2016 | Time: 9:00am – 1:00pm Workshop leader Dr. Jamie Hill  Senior Bioinformatics Scientist QIAGEN Workshop leader Dr. Jean-Noel Billaud  Principal Scientist QIAGEN Jamie Hill received a Master’s degree in Physics and a PhD in membrane protein structure prediction under the supervision of Professor CM Deane in the Statistics department of the University of Oxford. In 2014 he was awarded a Marie Curie postdoctoral fellowship at QIAGEN Aarhus. Today he is the Product Owner of QIAGEN’s CLC Genomics Workbench. Jean-Noel Billaud, Ph.D. is Principal Scientist at Qiagen Bioinformatics. He joined Ingenuity Systems (now QIAGEN) in 2008 as staff scientist for in silico research program in oncology and infectious diseases. Jean-Noel Billaud holds a Ph.D. in Blood Cell Biology from Paris VII, and has done his post-doctoral work at the Scripps Research Institute (San Diego, CA).
  9. 9. RNA-Seq Forum Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit Pre- Conference Workshop - B In recent years the role of the microbiota in health and disease is a field of research that has exploded with interest and opportunity. We now have a better understanding of how changes to the composition of our natural microbiome and their products impacts upon the initiation and development of disease. This has unlocked exciting new avenues for therapeutic intervention. In order to fully harness these new avenues of treatment, we must first advance our understanding of the specific role of microbiome communities in the progression of disease. Karsten Zengler will spearhead this dynamic and interactive session focussed on harnessing the power of RNA sequencing to provide detailed insight into the composition and function of the microbiota in a disease specific context. By attending this workshop, you will learn about and debate the following: • Analyzing microbiome signatures: identification of gene expression patterns in complex microbial communities • Deciphering the data: identifying strategies to maximize value output from microbiome RNA sequencing • On the origin of species: delineating and attributing patterns of gene expression within the microbiome community • Interpreting microbiota gene expression profiles to detail specific impacts on health and disease • Algorithm refining and streamlining to increase the speed of analysis and subsequent application of RNA sequencing in microbiome research • Clinically applying metatranscriptomics as a taxonomic biomarker and diagnostic tool • Developing gold standard universal microbiome RNA sequencing protocols to aid reproducibility and the verification of microbial influence in disease progression • Applying metatranscriptomics to guide drug discovery and development • Creating accurate software packages for Prokaryotic RNA sequencing analysis Attend this workshop to delve extensively into the subject matter, collaborate with fellow experts in the field, and hear a multitude of view points and experiences. You will leave better equipped to effectively utilize RNA sequencing to drive your microbiome disease research. Successfully Utilizing Metatranscriptomics to Advance Progression in Microbiome Disease Research Date: April 26, 2016 | Time: 2:00pm - 5:00pm Workshop leader Karsten Zengler Associate Professor, Division of Host-Microbe Systems & Therapeutics University of California, San Diego Karsten Zengler is Associate Professor in the Department of Pediatrics, Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego and member of the leadership team of the Center for Microbiome Innovation. Prof. Zengler has more than 15 years of experience in the fields of microbiology and systems biology. He worked for seven years in the biotechnology industry where he led a team of scientists to pioneer the high-throughput cultivation for the isolation and recovery of previously unculturable microorganisms. His work has focused on microbial ecology and understanding microorganism interactions with each other, their environment and their host. He spearheaded the field of community systems biology where he combined his knowledge in microbial physiology and molecular biology with computational biology to discover new physiological capabilities, regulatory effects, and novel mechanisms of interaction. Dr. Zengler is author and co-author of more than 50 research articles and reviews as well as editor of the book “Accessing Uncultivated Microorganisms”. He founded several companies and is on the advisory board of different companies and institutions
  10. 10. RNA-Seq Forum Commercial Partners Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit ® Clontech Clontech’s comprehensive collection of SMARTer® NGS kits is built on core SMART® technology, a powerful process that provides the ability to read full-length transcript information. With years of experience and a strong focus on improving the process of RNA-seq library preparation and the quality of data produced from every sample, this highly sensitive family of RNA-seq products is constantly growing in order to fulfill more demanding research needs. www.clontech.com Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com QIAGEN Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 20 countries. www.qiagen.com Fluidigm Fluidigm creates and manufactures innovative technologies and life-science tools designed to revolutionize biology through a relentless pursuit of scientific truth. Its core technologies are based on microfluidics and mass cytometry, and enable the exploration and analysis of individual cells, as well as the industrial application of genomics. Fluidigm partners with life science researchers and enterprises to provide simplified workflows for genomics and proteomics applications. Whether your quest is to understand the profiles and functions of single cells or to meet high-throughput data demands of a production- scale laboratory, you’ll find a solution at www.fluidigm.com Spotlight Partner Spotlight Partner Workshop Partner Lead Partner Exhibition Partner Genialis Genialis builds software that empowers the biologist or clinician to explore her data autonomously. Genialis Platform is a complete ecosystem for NGS data management, analysis, visualization and collaboration. The Platform boasts Real Time Interactive Visualizations, a technology we developed to enhance the user experience and improve the efficiency of data exploration and discovery. www.genialis.com
  11. 11. RNA-Seq Forum Commercial Partners Contact Us Contact Diane McKenna Portfolio Director - Genomics Tel: +1 212 537 5898 Email: sponsor@hansonwade.com Who you will meet... C-Level Director Level Academia Principal Scientist 64%20% 30%35% 15% Previous Attendance by Seniority Pharma Academia Solution Providers 20%50% 30% 20% Predicted Attendance by Sector Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit Seven Bridges Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including two of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot and Genomics England’s 100,000 Genomes Project. The company’s 187 experts work from its Cambridge, MA headquarters and offices in Belgrade, London and San Francisco. www.sbgenomics.com Dolomite Dolomite develops and manufactures innovative, open and versatile droplet systems for handling tens of thousands of single cells. Applications include high throughput single cell RNA sequencing, T Cell Receptor sequencing, high throughput antibody isolation, and encapsulation of cells in hydrogel beads for culture or enzymatic reactions. We offer modular, scalable systems ideal for Single Cell RNA-Seq and a range of chips, and installation and training. www.dolomite-microfluidics.com Exhibition Partner Exhibition Partner
  12. 12. RNA-Seq Forum Venue and Accommodation * All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU Hanson Wade Limited. Registered in England & Wales. Company No: 6752216 Terms & Conditions Register Event Prices Pricing & Venue Industry Register & Pay before Friday March 18, 2016 Standard Prices Conference + 2 Workshops $3597 (Save $500) $3797 (Save $300) Conference + Workshop $3098 (Save $300) $3198 (Save $200) Conference Only $2499 (Save $200) $2699 Workshop (each) $699 Academic Register & Pay before Friday March 18, 2016 Standard Prices Conference + 2 Workshops $2197 (Save $400) $2397 (Save $200) Conference + Workshop $1898 (Save £200) $1998 (Save $100) Conference Only $1499 (Save $100) $1599 Workshop (each) $499 Tel: +1 212 537 5898 Email: info@hansonwade.com www.rna-seqsummit.com RNA-Seq 2016 San Francisco | April 26-28, 2016 @RNASeq_Summit The Marker Hotel 501 Geary Street San Francisco California 94102 Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering. www.rna-seqsummit.com/register Tel: +1 212 537 5898 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU • 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team Discounts*

×